Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02903823 · ClinicalTrials.gov registry record · Phase 4

Intrathecal (IT) Baclofen Drug Distribution

A Phase 4 study, sponsored by Vanderbilt University.

Completed
Registry status
Phase 4
Development phase
27
Enrollment target

NCT02903823 is a Phase 4 study that has completed, run by Vanderbilt University. The registered enrollment target is 27 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02903823, a Phase 4 study, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
Phase 4
Development phase
27 participants
Enrollment target

Study Summary

The goal of this pilot study to determine whether there is a significant therapeutic advantage to place the ITB catheter within the cervical, thoracic or lumbar region of the spine. It is also a goal of this pilot study to determine whether the origin of spasticity influences the effect of Lioresal Intrathecal (baclofen injection) on ITB catheters located in the cervical, thoracic or lumbar regions of the spine. The investigators propose to study the impact of catheter location on the reduction in spasticity within a group of patients who are scheduled for ITB trial.

Interventions

  • DRUG Baclofen bolus injection

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2016-04-22
Est. Completion 2019-02-01
Phase Phase 4

Sponsor

Vanderbilt University

430 total trials

What the Registry Record Tells You About NCT02903823

The ClinicalTrials.gov registry entry for NCT02903823 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Baclofen bolus injection is the first listed.

NCT02903823 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02903823 about?

NCT02903823 is a clinical study titled "Intrathecal (IT) Baclofen Drug Distribution". The goal of this pilot study to determine whether there is a significant therapeutic advantage to place the ITB catheter within the cervical, thoracic or lumbar region of the spine. It is also a goal of this pilot study to determine whether the origin of spasticity influences the effect of Lioresal ...

What is the current status of trial NCT02903823?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2016-04-22. Estimated completion is 2019-02-01.

What interventions are being tested in trial NCT02903823?

The interventions under investigation include: Baclofen bolus injection (DRUG).

Who is sponsoring clinical trial NCT02903823?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.